Search Result

Results for "

ROCK2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ROCK (78) Akt (4) Apoptosis (6) Autophagy (9) Calcium Channel (6) Epigenetic Reader Domain (1) FOXO (1) G Protein-coupled Receptor Kinase (GRK) (3) HDAC (1) HIV (4) Isotope-Labeled Compounds (1) LIM Kinase (LIMK) (2) MMP (1) mTOR (3) Myosin (1) NADPH Oxidase (3) NF-κB (3) PAK (3) PI3K (1) PKA (9) PKC (10) PTEN (1) Ras (3) Reactive Oxygen Species (ROS) (3) Reference Standards (12) SGK (1) STAT (3) TGF-beta/Smad (1)
By Research Areas:	Cancer (38) Cardiovascular Disease (21) Endocrinology (2) Inflammation/Immunology (26) Metabolic Disease (3) Neurological Disease (14)

By Targets:

ROCK (78)

Akt (4)

Apoptosis (6)

Autophagy (9)

Calcium Channel (6)

Epigenetic Reader Domain (1)

FOXO (1)

G Protein-coupled Receptor Kinase (GRK) (3)

HDAC (1)

HIV (4)

Isotope-Labeled Compounds (1)

LIM Kinase (LIMK) (2)

MMP (1)

mTOR (3)

Myosin (1)

NADPH Oxidase (3)

NF-κB (3)

PAK (3)

PI3K (1)

PKA (9)

PKC (10)

PTEN (1)

Ras (3)

Reactive Oxygen Species (ROS) (3)

Reference Standards (12)

SGK (1)

STAT (3)

TGF-beta/Smad (1)

By Research Areas:

Cancer (38)

Cardiovascular Disease (21)

Endocrinology (2)

Inflammation/Immunology (26)

Metabolic Disease (3)

Neurological Disease (14)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: ROCK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10071

Y-27632 Maximum Cited Publications 533 Publications Verification	ROCK NADPH Oxidase mTOR Reactive Oxygen Species (ROS) NF-κB Apoptosis Akt Autophagy PAK Ras	Cancer
Y-27632 is a *ROCK* inhibitor with K_i values of 220 nM and 300 nM for *ROCK1* and *ROCK2, respectively. Y-27632 exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting* the *ROCK/NF-κB* pathway. Y-27632 enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade .

HY-15307

Belumosudil 30+ Cited Publications KD025; SLx-2119	ROCK	Inflammation/Immunology Cancer
Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-15392

Chroman 1 60+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 is a highly potent and selective *ROCK* inhibitor. Chroman 1 is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-10341

Fasudil Hydrochloride 25+ Cited Publications HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-103045

CMPD101 4 Publications Verification	ROCK PKC G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC₅₀ of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC₅₀s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure .

HY-15556

GSK269962A 5+ Cited Publications GSK 269962	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A (GSK 269962) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A has anti-inflammatory and vasodilatory activities .

HY-10341A

Fasudil 25+ Cited Publications HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-148808

Zelasudil RXC007	ROCK	Cancer
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .

HY-15307A

Belumosudil mesylate 30+ Cited Publications KD025 mesylate; SLx-2119 mesylate	ROCK	Inflammation/Immunology
Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-15720A

H-1152 dihydrochloride 4 Publications Verification	ROCK	Neurological Disease
H-1152 dihydrochloride is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-15685

Ripasudil 5+ Cited Publications K-115	ROCK	Cardiovascular Disease Neurological Disease
Ripasudil (K-115) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-15755

RKI-1447 4 Publications Verification	ROCK	Cancer
RKI-1447 is a potent small molecule inhibitor of *ROCK1* and *ROCK2* with IC₅₀ values of 14.5 nM and 6.2 nM, respectively.

HY-10319

BAY-549 4 Publications Verification ROCK-IN-2; Azaindole 1; TC-S 7001	ROCK	Cardiovascular Disease
BAY-549 (Azaindole 1), a chemical probe, is an orally active and ATP-competitive *ROCK* inhibitor with IC₅₀s of 0.6 and 1.1 nM for human *ROCK-1* and *ROCK-2*, respectively .

HY-119937

ROCK inhibitor-2 2 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC₅₀ values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC₅₀ of 75 nM. ROCK inhibitor-2 exhibits antitumor activity .

HY-15687A

SAR407899 3 Publications Verification	ROCK	Metabolic Disease
SAR407899 is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively. SAR407899 shows stable inhibition of migrasome formation.

HY-162596

NRL-1049 BA-1049 free base	ROCK	Neurological Disease
NRL-1049 (BA-1049 (free base)) is an orally available and selective *ROCK2* inhibitor with IC₅₀ values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .

HY-108518

SB-772077B dihydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology
SB-772077B dihydrochloride is an orally active aminofuran-based Rho kinase ((ROCK)) inhibitor with IC₅₀ values of 5.6 nM and 6 nM for ROCK1 and ROCK2, respectively. SB-772077B dihydrochloride reduces inflammatory cytokines (TNF-α and IL-6). SB-772077B dihydrochloride relaxes aortic rings and lowers blood pressure. SB-772077B dihydrochloride can be used in the research of inflammatory diseases .

HY-13911

Hydroxyfasudil 5 Publications Verification HA-1100	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-15720

H-1152 4 Publications Verification	ROCK	Neurological Disease
H-1152 is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-103620

ROCK2-IN-2	ROCK	Inflammation/Immunology Cancer
ROCK2-IN-2 (Example 2) is a *ROCK2* inhibitor that can be used for the study of multiple medical disorders, such as fibrosis, inflammatory disorders, autoimmune disorders, and cardiovascular disorders .

HY-13911A

Hydroxyfasudil hydrochloride 5 Publications Verification HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil hydrochloride is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-12437

BDP5290	ROCK	Cancer
BDP5290 is a potent inhibitor of both *ROCK* and MRCK with IC₅₀s of 5 nM, 50 nM, 10 nM and 100 nM for *ROCK1, ROCK2, MRCKα* and MRCKβ, respectively.

HY-15556A

GSK269962A hydrochloride 5+ Cited Publications GSK 269962 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .

HY-100270

Rho-Kinase-IN-1	ROCK	Cancer
Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor (K_i values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively) extracted from US20090325960A1, compound 1.008 .

HY-16758

Verosudil AR-12286	ROCK	Neurological Disease
Verosudil (AR-12286) is a *ROCK* inhibitor. Verosudil has equal inhibitory activity against ROCK1 and ROCK2 (K_i: 2 nM). Verosudil is less selective for PKA, PKCT, MRCKA, and CAM2A (K_i: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil increases trabecular outflow capacity to reduce intraocular pressure. Verosudil is useful in the study of glaucoma and ocular hypertension .

HY-10341C

Fasudil dihydrochloride 25+ Cited Publications HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific *RhoA/ROCK* inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for *ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2* and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca ²⁺ channel antagonist and vasodilator .

HY-12659

LX7101 3 Publications Verification	LIM Kinase (LIMK) ROCK PKA	Endocrinology
LX7101 is a potent LIM-kinase, *ROCK* and PKA inhibitor with IC₅₀s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 proves significantly selective for LIMK2 with IC₅₀ values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 has the potential for ocular hypertension and associated glaucoma research .

HY-15687

SAR407899 hydrochloride 3 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively.

HY-149266

THK01 1 Publications Verification	ROCK	Cancer
THK01 is a potent *ROCK2* inhibitor with IC₅₀ values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. THK01 inhibits breast cancer metastasis through the ROCK2-STAT3 signaling pathway. THK01 can be used in research of breast cancer .

HY-150640

Rho-Kinase-IN-2	ROCK	Neurological Disease Inflammation/Immunology Cancer
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and CNS-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC₅₀ = 3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .

HY-15392A

Chroman 1 dihydrochloride 60+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 dihydrochloride is a highly potent and selective *ROCK* inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-178821

ROCK2-IN-12	ROCK TGF-beta/Smad STAT	Inflammation/Immunology
ROCK2-IN-12 (Compound A25) is a selective *ROCK2* inhibitor with an IC₅₀ of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and *ROCK2/STAT3* signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .

HY-156592A

ROCK2-IN-6 hydrochloride	ROCK	Inflammation/Immunology
ROCK2-IN-6 hydrochloride (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-126432

NRL-1049 dihydrochloride BA-1049	ROCK	Neurological Disease
NRL-1049 dihydrochloride (BA-1049) is a selective and orally active rho-associated protein kinase 2 (ROCK2) inhibitor with an IC₅₀ of 0.59 μM. NRL-1049 dihydrochloride shows selectivity for ROCK2 is 44 times that of ROCK1 (IC₅₀ = 26 μM). NRL-1049 dihydrochloride can preserve the blood-brain barrier after acute injury .

HY-116420

ROCK2-IN-8	ROCK	Neurological Disease
ROCK2-IN-8 (Compound 1) is an orally active *ROCK2* inhibitor, with an IC₅₀ of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .

HY-110339

RKI-1447 dihydrochloride 4 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective *ROCK* inhibitor with IC₅₀s of 14.5 and 6.2 nM for *ROCK1* and *ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis* .

HY-178013

ROCK2-IN-11	ROCK	Inflammation/Immunology
ROCK2-IN-11 (Compound A20) is a selective *ROCK2* inhibitor with an IC₅₀ of 0.18 μM for ROCK2 over ROCK1. ROCK2-IN-11 can be used for idiopathic pulmonary fibrosis and cGVHD research .

HY-10071A

Y-27632 hydrochloride hydrate 395+ Cited Publications	ROCK NF-κB Apoptosis Autophagy Akt mTOR NADPH Oxidase Reactive Oxygen Species (ROS) PAK Ras	Neurological Disease Inflammation/Immunology Cancer
Y-27632 hydrochloride hydrate is a *ROCK* inhibitor with K_i values of 220 nM and 300 nM for *ROCK1* and *ROCK2, respectively. Y-27632 hydrochloride hydrate exerts anti-inflammatory and immunomodulatory effects in systemic lupus erythematosus models by inhibiting* the *ROCK/NF-κB* pathway. Y-27632 hydrochloride hydrate enhances autophagy by inhibiting the AKT/mTOR pathway, thereby inducing apoptosis apoptosis in oral squamous cell carcinoma. Y-27632 hydrochloride hydrate induces the formation of tunneling nanotubes in ARPE-19 cells and significantly enhances mitochondrial transfer through these channels. Y-27632 hydrochloride hydrate promotes neurite outgrowth in PC12 cells by activating the Rac1/NOX1/ROS/AKT/PAK1 signaling cascade .

HY-15685A

Ripasudil free base K-115 free base	ROCK	Neurological Disease
Ripasudil free base (K-115 free base) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-126275

HSD1590	ROCK	Cancer
HSD1590 is potent *ROCK* inhibitor, with IC₅₀s of 1.22 and 0.51 nM for ROCK1 and ROCK2, respectively. HSD1590 exhibits single digit nanomolar binding to ROCK (K_ds<2 nM). HSD1590 displays low cytotoxicity .

HY-175843

ROCK2-IN-10	ROCK STAT	Cancer
ROCK2-IN-10 is a potent and selective *ROCK2* inhibitor (IC₅₀ = 0.020 μM) with 41-fold selectivity over isoform ROCK1. ROCK2-IN-10 inhibits metastasis by disrupting the cytoskeleton, independent of proliferative suppression. ROCK2-IN-10 shows superior inhibitory potency against cancer cell metastasis, which closely related to the suppression of STAT3 phosphorylation. ROCK2-IN-10 can be used for breast cancer metastasis research .

HY-15307AR

Belumosudil mesylate (Standard) KD025 mesylate (Standard); SLx-2119 mesylate (Standard)	ROCK Reference Standards	Inflammation/Immunology Cancer
Belumosudil (mesylate) (Standard) is the analytical standard of Belumosudil (mesylate). This product is intended for research and analytical applications. Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-15307R

Belumosudil (Standard) KD025 (Standard); SLx-2119 (Standard)	ROCK Reference Standards	Inflammation/Immunology Cancer
Belumosudil (Standard) is the analytical standard of Belumosudil. This product is intended for research and analytical applications. Belumosudil (KD025) is a selective inhibitor of ROCK2 with IC50s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-U00351

ROCK-IN-1 1 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK-IN-1 is a potent inhibitor of *ROCK, with an IC₅₀* of 1.2 nM for ROCK2.

HY-149700

ROCK2-IN-7	ROCK MMP STAT	Others
ROCK2-IN-7 is a kinase inhibitor targeting to *ROCK2. ROCK2-IN-7* inhibits ROCK2/pSTAT3 Signaling. ROCK2-IN-7 suppresses systemic immunity activation and attenuates inflammation in psoriasis model .

HY-162798

ROCK2-IN-9	ROCK	Cancer
ROCK2-IN-9 (compound 7u) is a selective *ROCK2* inhibitor (IC₅₀=36.8 nM) with anticancer activity. ROCK2-IN-9 inhibits cancer cell migration and invasion by regulating multiple cellular activities of the actin cytoskeleton. ROCK2-IN-9 can be used in breast cancer research .

HY-15685R

Ripasudil (Standard) K-115 (Standard)	ROCK Reference Standards	Cardiovascular Disease Neurological Disease
Ripasudil (Standard) is the analytical standard of Ripasudil. This product is intended for research and analytical applications. Ripasudil (K-115) is a specific inhibitor of ROCK, with IC50s of 19 and 51 nM for ROCK2 and ROCK1, respectively.

HY-10833

ROCK-IN-10	ROCK	Cardiovascular Disease
ROCK-IN-10 (compound 50) is a potent *ROCK* inhibitor with IC₅₀ values of 6 nM and 4 nM for ROCK1 and ROCK2, respectively. ROCK-IN-10 shows >100-fold selectivity against other kinases .

HY-122011

PF-4950834	ROCK SGK PKA PKC	Inflammation/Immunology
PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC₅₀ values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration .

HY-103045A

CMPD101 hydrochloride	PKC ROCK G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CMPD101 hydrochloride is a novel membrane-permeable, small-molecule inhibitor of both GRK2 and GRK3 with IC₅₀s of 18 nM and 5.4 nM, respectively. CMPD101 hydrochloride also inhibits Rho-associated kinase 2 (ROCK-2) and PKCα (IC₅₀s =1.4 μM and 8.1 μM, respectively) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15301

Nocarnickelamide B	Microorganisms Ketones, Aldehydes, Acids Source Classification	ROCK Myosin
Nocarnickelamide B (Compound 2) is a linear peptide and *ROCK1/2* inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against *ROCK1* and *ROCK2* with IC₅₀s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .

Cat. No.	Product Name	Chemical Structure

HY-15307S

Belumosudil-d7
Belumosudil-d₇ (KD025-d₇) is deuterium labeled Belumosudil. Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks